vs
百利高（PRGO）与RENAISSANCERE HOLDINGS LTD（RNR）财务数据对比。点击上方公司名可切换其他公司
RENAISSANCERE HOLDINGS LTD的季度营收约是百利高的2.0倍（$2.2B vs $1.1B），RENAISSANCERE HOLDINGS LTD净利率更高（23.5% vs -127.8%，领先151.3%），百利高同比增速更快（-2.5% vs -36.8%），过去两年百利高的营收复合增速更高（1.3% vs -11.9%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
RenaissanceRe Holdings Ltd是总部位于百慕大的保险及相关商业服务提供商，核心业务覆盖再保险、常规保险两大板块，同时运营风险相关创新投资业务，为全球客户提供专业的风险对冲与保险解决方案。
PRGO vs RNR — 直观对比
营收规模更大
RNR
是对方的2.0倍
$1.1B
营收增速更快
PRGO
高出34.2%
-36.8%
净利率更高
RNR
高出151.3%
-127.8%
两年增速更快
PRGO
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.2B |
| 净利润 | $-1.4B | $515.8M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | — |
| 净利率 | -127.8% | 23.5% |
| 营收同比 | -2.5% | -36.8% |
| 净利润同比 | -3093.9% | 72.6% |
| 每股收益（稀释后） | $-10.23 | $6.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORNR
| Q1 26 | — | $2.2B | ||
| Q4 25 | $1.1B | $3.0B | ||
| Q3 25 | $1.0B | $3.2B | ||
| Q2 25 | $1.1B | $3.2B | ||
| Q1 25 | $1.0B | $3.5B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $1.1B | $4.0B | ||
| Q2 24 | $1.1B | $2.8B |
净利润PRGORNR
| Q1 26 | — | $515.8M | ||
| Q4 25 | $-1.4B | $760.5M | ||
| Q3 25 | $7.5M | $916.5M | ||
| Q2 25 | $-8.4M | $835.4M | ||
| Q1 25 | $-6.4M | $170.0M | ||
| Q4 24 | $-44.4M | $-189.7M | ||
| Q3 24 | $-21.0M | $1.2B | ||
| Q2 24 | $-108.4M | $503.9M |
毛利率PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — |
营业利润率PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | -116.0% | 42.5% | ||
| Q3 25 | 7.0% | 46.3% | ||
| Q2 25 | 4.3% | 41.8% | ||
| Q1 25 | 4.5% | -2.0% | ||
| Q4 24 | 10.0% | -3.6% | ||
| Q3 24 | 7.4% | 43.7% | ||
| Q2 24 | -2.5% | 25.0% |
净利率PRGORNR
| Q1 26 | — | 23.5% | ||
| Q4 25 | -127.8% | 25.6% | ||
| Q3 25 | 0.7% | 28.7% | ||
| Q2 25 | -0.8% | 26.1% | ||
| Q1 25 | -0.6% | 4.9% | ||
| Q4 24 | -3.9% | -8.3% | ||
| Q3 24 | -1.9% | 29.8% | ||
| Q2 24 | -10.2% | 17.8% |
每股收益（稀释后）PRGORNR
| Q1 26 | — | $6.57 | ||
| Q4 25 | $-10.23 | $16.16 | ||
| Q3 25 | $0.05 | $19.40 | ||
| Q2 25 | $-0.06 | $17.20 | ||
| Q1 25 | $-0.05 | $3.27 | ||
| Q4 24 | $-0.32 | $-3.76 | ||
| Q3 24 | $-0.15 | $22.62 | ||
| Q2 24 | $-0.79 | $9.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $4.3B |
| 总资产 | $8.5B | $53.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGORNR
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.7B | ||
| Q3 25 | $432.1M | $1.7B | ||
| Q2 25 | $454.2M | $1.4B | ||
| Q1 25 | $409.9M | $1.6B | ||
| Q4 24 | $558.8M | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $542.8M | $1.6B |
总债务PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.0B |
股东权益PRGORNR
| Q1 26 | — | $4.3B | ||
| Q4 25 | $2.9B | $11.6B | ||
| Q3 25 | $4.4B | $11.5B | ||
| Q2 25 | $4.5B | $10.8B | ||
| Q1 25 | $4.4B | $10.3B | ||
| Q4 24 | $4.3B | $10.6B | ||
| Q3 24 | $4.6B | $11.2B | ||
| Q2 24 | $4.5B | $10.2B |
总资产PRGORNR
| Q1 26 | — | $53.7B | ||
| Q4 25 | $8.5B | $53.8B | ||
| Q3 25 | $10.1B | $54.5B | ||
| Q2 25 | $10.1B | $54.7B | ||
| Q1 25 | $9.8B | $53.6B | ||
| Q4 24 | $9.6B | $50.7B | ||
| Q3 24 | $11.2B | $52.8B | ||
| Q2 24 | $10.4B | $51.6B |
负债/权益比PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | — |
| 自由现金流经营现金流 - 资本支出 | $148.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | $175.4M | $483.0M | ||
| Q3 25 | $51.7M | $1.6B | ||
| Q2 25 | $75.9M | $1.5B | ||
| Q1 25 | $-64.5M | $157.8M | ||
| Q4 24 | $312.6M | $778.9M | ||
| Q3 24 | $42.2M | $1.5B | ||
| Q2 24 | $9.5M | $1.2B |
自由现金流PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — |
自由现金流率PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — |
资本支出强度PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — |
现金转化率PRGORNR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.64× | ||
| Q3 25 | 6.89× | 1.73× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RNR
暂无分部数据
